The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infectionSam Hopkins, Philippe Gallay, Bernard Scorneaux et al.|Journal of Hepatology|2012Cited by 92
Host-targeting agents in the treatment of hepatitis C: A beginning and an end?James Baugh, Philippe Gallay, Jose A. Garcia-Rivera|Antiviral Research|2013Cited by 48
The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-ResistanceUdayan Chatterji, Philippe Gallay, Jose A. Garcia-Rivera et al.|Antimicrobial Agents and Chemotherapy|2014Cited by 37
HCV NS5A and IRF9 compete for CypA bindingMichael Bobardt, Philippe Gallay, Sam Hopkins et al.|Journal of Hepatology|2012Cited by 28
HCV Core Residues Critical for Infectivity Are Also Involved in Core-NS5A Complex FormationKatarzyna Gawlik, Philippe Gallay, James Baugh et al.|PLoS ONE|2014Cited by 24